3 Reasons Why GlaxoSmithKline plc And AstraZeneca plc Are Worth Buying Right Now

These 2 pharmaceutical stocks could deliver stunning share price gains: GlaxoSmithKline plc (LON: GSK) and AstraZeneca plc (LON: AZN)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

While Pfizer’s bid for AstraZeneca (LSE: AZN) (NYSE: AZN.US) did not come off last year, both it and sector peer GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) could prove to be realistic bid targets moving forward.

The reason for this is fairly simple: a number of larger pharmaceutical companies are struggling to deliver top and bottom line growth, thereby making acquisition-led growth a relatively appealing option. And, with robust balance sheets and very attractive rates of borrowing still on offer, this year could prove to be the best chance of securing bid targets before interest rates begin to move higher.

As such, AstraZeneca and GlaxoSmithKline could see their share prices head north as investors begin to include a bid premium in their valuations.

New Strategies

As well as being bid targets, AstraZeneca and GlaxoSmithKline are also adopting strategies that could unlock considerable shareholder value. In AstraZeneca’s case, it has made multiple bolt-on acquisitions in recent years and continues to have the financial firepower to make more. This is helping it to overcome its Achilles heel: the loss of key, blockbuster drugs that has caused its top and bottom lines to fall heavily. And, as a result of its new strategy, AstraZeneca expects to begin growing by 2017, which would represent an impressive turnaround.

Meanwhile, GlaxoSmithKline’s plans to rationalise its business and potentially spin-off faster growing divisions (such as ViiV health care) and reduce its reliance on consumer goods could prove to be a prudent move. Certainly, it may leave it more exposed to the peaks and troughs of the drug development cycle but, with a promising pipeline of new drugs, it should be able to deliver strong growth moving forward.

Cost Reduction

As with any business that is struggling to grow its top line, cost cutting has become an integral part of AstraZeneca and GlaxoSmithKline’s focus in recent years. For example, GlaxoSmithKline continues to target £1bn of cost savings in its prescription-drug division over the next three years, while AstraZeneca is aiming to deliver £520m of cost reductions as it seeks to reduce its headcount by 5,000 over the next couple of years.

Looking Ahead

So, with AstraZeneca and GlaxoSmithKline both having the potential to become bid targets during the course of the year, adopting very sound strategies that could boost their bottom lines, and also having the potential to make significant cost savings, now could be a great time to buy shares in both companies.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

High flying easyJet women bring daughters to work to inspire next generation of women in STEM
Investing Articles

In 12 months, a £10,000 investment in easyJet shares could become…

easyJet shares have plunged in value following a profit warning on Thursday (17 July). Can the FTSE 100 travel share…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

This S&P 500 blue chip looks far too cheap to me at $183!

Our writer picks out one high-quality S&P 500 stock that is currently the cheapest among the 'Magnificent 7' group of…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Down 23% today! This one’s stinking out my Stocks and Shares ISA

Our writer's wondering what to do with a problem named Ashtead Technology (LON:AT.) in his Stocks and Shares ISA portfolio.

Read more »

Two male friends are out in Tynemouth, North East UK. They are walking on a sidewalk and pushing their baby sons in strollers. They are wearing warm clothing.
Investing Articles

Down over 20%, should I dump this FTSE 100 dividend stock?

Our writer has been loving the passive income this dividend stock has been throwing off. But does the big share…

Read more »

Businesswoman calculating finances in an office
Investing Articles

I’ve just bought this FTSE share…

Our writer explains the thought process that led to him buying this FTSE share. One that’s likely to do well…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Just over £5 now, easyJet’s share price looks cheap to me anywhere under £13.84

easyJet’s share price has dropped recently, which could mean the business is worth less than before. Conversely, it could mean…

Read more »

Trader on video call from his home office
Investing Articles

36% under ‘fair value’ and forecast annual earnings growth of 6%, should investors consider this FTSE 250 stock?  

This FTSE 250 firm is a leader in a growing sector and has secured several new sites to drive its…

Read more »

Portrait of a boy with the map of the world painted on his face.
Investing Articles

3 UK shares that have recently become takeover targets

Mark Hartley examines why these three UK shares have become takeover targets and could be bought out by rivals in…

Read more »